LCTX

Business Context and Reporting Period

Company: BioTime, Inc. (Note: Input metadata referenced "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.)
Period: Fiscal year ended December 31, 2004
Business Overview: BioTime is a biomedical organization developing synthetic plasma expanders, blood volume substitutes, and organ preservation solutions. Its primary commercial product is Hextend, a plasma volume expander licensed to Hospira (North America) and CJ Corp. (South Korea). The company is also developing PentaLyte (plasma expander) and HetaCool (hypothermic blood substitute/organ preservative).

Key Financial Metrics

Note: The company had no long-term debt as of December 31, 2004, following the retirement of $3.35 million in debentures in February 2004.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 24% to $688,377, driven by a 15% increase in royalties from Hospira ($589,517 vs. $514,235) and the recognition of $78,700 in license fees from CJ Corp. (South Korea).
• Increased Loss: Net loss widened by 77% to $3.1 million. This was primarily due to a $1.1 million charge for the extinguishment of debt and increased operating expenses.
• Expense Increases:
  • R&D Expenses: Rose 24% to $1.12 million, largely due to Phase II trial preparations for PentaLyte.
  • G&A Expenses: Rose 18% to $1.48 million, driven by new executive hires, increased investor relations costs, and financial advisory fees.
• Debt Elimination: The company eliminated all debenture indebtedness ($3.35 million) using proceeds from a January 2004 rights offering and share conversions.
• Equity Position: Shareholders' equity turned positive ($344,770) from a deficit of $(2.43 million) in 2003, following a rights offering that raised gross proceeds of $4.18 million.

Outlook, Risks, and Management Commentary

• Liquidity: Management estimates cash on hand ($1.37 million) plus receivables and anticipated royalties will fund operations for approximately 15 months (through mid-2006). Additional capital will be required to complete clinical trials for PentaLyte and HetaCool.
• Product Pipeline:
  • PentaLyte: Phase II clinical trials are commencing; estimated cost is at least $1 million.
  • HetaCool: Development continues for hypothermic surgery and organ preservation. An NIH grant of $150,000 was awarded in 2004.
• Listing Risk: The company is not in compliance with American Stock Exchange (AMEX) continued listing standards regarding shareholders' equity (requires $6 million) and profitability. An extension was granted until April 2005 to regain compliance. Failure to comply could result in delisting and trading under "penny stock" rules.
• Management Structure: Following the death of CEO Paul Segall in 2003, the company is led by an "Office of the President" (three founders) to avoid the cost of a new CEO until cash flow improves.
• Revenue Recognition: Royalties are recognized when sales reports are received (typically 90 days after the quarter of sale), creating a lag in reported revenue.

Key Facts for Investor Verification

• Listing Status: Verify if the company regained AMEX compliance by the April 2005 deadline to avoid delisting.
• Cash Runway: Confirm the 15-month liquidity estimate against actual burn rates and the timing of royalty receipts from Hospira.
• Clinical Trial Costs: Monitor the actual costs of the PentaLyte Phase II trials, which are estimated at $1 million but could exceed this amount.
• License Agreements: Review the status of the CJ Corp. license in South Korea (sales began Q1 2005) and the Summit Pharmaceuticals agreement for the Japanese market.
• Debt-Free Status: Confirm the company remains free of long-term debt obligations.